177 related articles for article (PubMed ID: 14981927)
1. EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
Knecht R; Peters S; Solbach C; Baghi M; Gstöttner W; Hambek M
Anticancer Res; 2003; 23(6C):4789-95. PubMed ID: 14981927
[TBL] [Abstract][Full Text] [Related]
2. EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
Knecht R; Peters S; Hambek M; Solbach C; Baghi M; Gstöttner W; Hambek M
Adv Otorhinolaryngol; 2005; 62():81-91. PubMed ID: 15608420
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.
Bozec A; Sudaka A; Etienne-Grimaldi MC; Brunstein MC; Fischel JL; Milano G
Oral Oncol; 2011 Oct; 47(10):940-5. PubMed ID: 21862388
[TBL] [Abstract][Full Text] [Related]
4. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Haddad R; Tishler R; Wirth L; Norris CM; Goguen L; Sullivan C; O'Donnell L; Li Y; Posner M
Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):678-81. PubMed ID: 16785415
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
[TBL] [Abstract][Full Text] [Related]
6. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.
Baghi M; Hambek M; May A; Radeloff A; Gstoettner W; Knecht R
Anticancer Res; 2006; 26(1B):559-63. PubMed ID: 16739320
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel in squamous cell cancer of the head and neck.
Posner MR
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S21-4. PubMed ID: 11340900
[TBL] [Abstract][Full Text] [Related]
11. Polymer chemotherapy for head and neck cancer.
Shikani AH; Domb AJ
Laryngoscope; 2000 Jun; 110(6):907-17. PubMed ID: 10852503
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
[TBL] [Abstract][Full Text] [Related]
13. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
Baghi M; Hambek M; Wagenblast J; May A; Gstoettner W; Knecht R
Anticancer Res; 2006; 26(1B):585-90. PubMed ID: 16739325
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?
Paccagnella A; Mastromauro C; D'Amanzo P; Ghi MG
Oncologist; 2010; 15 Suppl 3():8-12. PubMed ID: 21036883
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
Lin JT; Lai GM; Chang TH; Liu MT; Bi CP; Wang JW; Chen MK
Adv Ther; 2012 Jan; 29(1):71-7. PubMed ID: 22161550
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.
Shin DM; Donato NJ; Perez-Soler R; Shin HJ; Wu JY; Zhang P; Lawhorn K; Khuri FR; Glisson BS; Myers J; Clayman G; Pfister D; Falcey J; Waksal H; Mendelsohn J; Hong WK
Clin Cancer Res; 2001 May; 7(5):1204-13. PubMed ID: 11350885
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.
Hoffmann T; Hafner D; Ballo H; Haas I; Bier H
Anticancer Res; 1997; 17(6D):4419-25. PubMed ID: 9494544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
